Alendronate and pharmacological doses of 1alpha OHD3 therapy in a patient with McCune-Albright syndrome and accompanying hypophosphatemia.
Yamamoto
Takehisa
T
Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Ozono
Keiichi
K
Shima
Masaaki
M
Yoshikawa
Hideki
H
Okada
Shintaro
S
D000328:Adult; D019386:Alendronate / Q000627:therapeutic use*; D001842:Bone and Bones / Q000000981:diagnostic imaging; D017610:Calcium Compounds / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005359:Fibrous Dysplasia, Polyostotic / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D017674:Hypophosphatemia / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D007773:Lactates / Q000627:therapeutic use; D010710:Phosphates / Q000627:therapeutic use; D011877:Radionuclide Imaging
D017610:Calcium Compounds; D006887:Hydroxycholecalciferols; D007773:Lactates; D010710:Phosphates; C110051:calcium lactate; C008088:alfacalcidol; D019386:Alendronate